ERBB2 and breast carcinoma: Based on the impressive improvement on PFS, everolimus in combination with exemestane was approved for the treatment of postmenopausal HR+/HER2- advanced breast cancer patients recurring or progressing on prior NSAIs in the USA and European Union.